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Abstract
c-Yes, a member of the Src tyrosine kinase family, is found highly activated in colon carcinoma but its importance relative to
c-Src has remained unclear. Here we show that, in HT29 colon carcinoma cells, silencing of c-Yes, but not of c-Src, selectively
leads to an increase of cell clustering associated with a localisation of b-catenin at cell membranes and a reduction of
expression of b-catenin target genes. c-Yes silencing induced an increase in apoptosis, inhibition of growth in soft-agar and
in mouse xenografts, inhibition of cell migration and loss of the capacity to generate liver metastases in mice. Re-
introduction of c-Yes, but not c -Src, restores transforming properties of c-Yes depleted cells. Moreover, we found that c-Yes
kinase activity is required for its role in b-catenin localisation and growth in soft agar, whereas kinase activity is dispensable
for its role in cell migration. We conclude that c-Yes regulates specific oncogenic signalling pathways important for colon
cancer progression that is not shared with c-Src.
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Introduction
Cytoplasmic tyrosine kinases of the Src family (SFKs) play
important roles in signal transduction induced by a large number
of extracellular stimuli including growth factors and integrins
[1,2]. They include 8 cellular members, c-Src, Fyn and c-Yes
being widely expressed. SFKs contain a unique N-terminus with
a myristoylation site required for membrane localisation, SH3
and SH2 domains used for protein-protein interactions, a
catalytic domain and a C-terminal Tyr residue, that when
phosphorylated by Csk, inhibits kinase activity [3]. SFKs also
exhibit oncogenic activity when deregulated, a situation fre-
quently observed in human cancer. Remarkably, elevated SFK
activity is found in more than 80% of human colorectal cancer
(CRC) and this has been associated with poor clinical outcome
[4]. c-Src deregulation is thought to be an important event for
colon tumorigenesis tumour growth, angiogenesis and metastasis
[4]. Therefore, c-Src is an attractive therapeutic target and
several small molecule inhibitors are currently being tested in
clinical trials [5].
The SFK member c-Yes is the cellular counterpart of the viral
v-Yes protein encoded by the Yamaguchi avian sarcoma virus
[6]. c-Yes exhibits the highest homology with c-Src among SFK
members, with 70% identity outside the N-terminus. As in v-Src,
a C-terminal truncation in v-Yes removes the negative regulatory
Tyr allowing the kinase to be constitutively active and highly
oncogenic. While such activating mechanism has not been
reported in human cancer, c-Yes is found frequently activated
in CRC. Remarkably, c-Yes activation in CRC correlates more
closely with poor prognosis [7,8] than does c-Src activation.
Despite the above evidence suggesting a role for c-Yes in CRC,
functional data supporting this notion are missing. The majority
of data published on SFKs has focused on c-Src and it has been
generally accepted that c-Yes may be redundant in malignancies.
This idea has been supported by gene knock-out experiments in
mice and corresponding embryonic fibroblasts, which pointed to
partial redundant functions during embryogenesis [9] and cellular
division [10]. The major structural difference between these
SFKs lies in the unique N-terminus with additional palmitoyla-
tion site present in c-Yes and absent in c-Src [1]. This post-
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17237translational modification stabilises c-Yes in specific sub-cellular
compartments, including cholesterol-enriched membrane do-
mains present at tight and adherent junctions [11]. Due to the
absence of such lipid attachment, c-Src shows higher mobility at
membranes and therefore is localised at focal adhesions [12].
Thus, membrane partitioning may contribute to unique signalling
emanating from these SFKs.
Several lines of evidence point to selective functions for c-Yes
in cellular signalling leading to transcytosis and cell-cell adhesions
[13]. For instance, c-Yes, and not c-Src is reported to form a
calcium-dependent complex with occludin at tight junctions [14].
A role of c-Yes in adherens junctions has been revealed in yes-/-
mice. Although no obvious phenotype was initially observed [9],
it was found that deletion of c-Yes led to decreased vascular
permeability leading to lower extravasation of tumour cells and
reduced leakeage during ischemia [15]. It has also been reported
that pharmacological inhibition of SFKs with pan-SFK com-
pounds increases cell-cell adhesion via an elevation of E-cadherin
and VE-cadherin in epithelial or in endothelial cell-cell junctions
respectively [16,17,18,19]. Whether c-Src or c-Yes has a selective
role in cell-cell adhesion of tumour cells and more generally in
carcinogenesis is largely unknown. Here we have used an RNA
interference approach to address the specific function of c-Yes in
CRC cells. We show in HT29 cells that, despite high endogenous
levels of deregulated c-Src activity, c-Yes drives selective
oncogenic signalling required for transformed phenotype of these
cancer cells including cell-cell adhesion, growth/survival and
invasion.
Results
Knock-down of c-Yes results in cell clustering of colon
cancer cells
We first measured c-Yes expression in various CRC cells-lines.
HT29 was found to express the highest amount of c-Yes among
cells tested (Fig. 1A), therefore this cell-line was used to address
c-Yes oncogenic signalling in CRC cells. A comparison of c-Src
and c-Yes mRNA levels indicated that these cells contain 3.8-
times higher c-Src levels, suggesting that c-Yes represents at
most, 25% of the SFK pool in HT29 cells (Fig. S1A). The
selective function of c-Yes was next addressed by depleting c-Yes
levels by the use of a specific shRNA. c-Yes protein expression
was reduced by 85–90% (Fig. 1B and Fig. S1), without affecting
c-Src expression. Cellular infection with retroviruses expressing
shRNA targeting c-Src gave a milder reduction in Src expression
(70–75%) without affecting c-Yes level (Fig. 1B and Fig. S1).
Since it has been shown previously that pharmacological
inhibition of SFKs results in formation of cell clusters
[17,19,20] we examined the formation of clusters by Differential
Interference Contrast microscopy. Interestingly, c-Yes knock-
down was sufficient to induce formation of cell clusters (Fig. 1C).
Confocal microscopy revealed that c-Yes knock-down-induced
clusters containing up to five layers of cells (Fig. 1D). Similar
effects were observed when silencing c-Yes with transient
transfection of individual siRNA sequences (Fig. S2), indicating
that these inhibitory effects were not due to off-target and/or
long-term depletion of c-Yes. In contrast, c-Src knock-down
resulted in a mild effect on the morphology of the cell monolayer
(Fig. 1C and Fig. S2C), suggesting that the role of c-Yes on this
cellular process is not shared by c-Src. Besides c-Src and c-Yes,
Lyn, but not Fyn, is also detected in HT29 cells. We then
examined the role of Lyn in cell adhesions with a similar siRNA
strategy. Although Lyn knock-down was very efficient, there was
no impact on cell morphology (Fig. S3B). Taken together, these
data point to a selective role of c-Yes in the modulation of HT29
cell adhesive properties.
c-Yes knock-down strengthens b-catenin accumulation
at cell-cell junctions
We next investigated the effect of c-Yes depletion on cell
clustering in further detail. SFKs, and in particular c-Src, have
been described as important regulators of focal adhesions via
recruitment by FAK auto-phosphorylated on Tyr397. This
recruitment leads to phosphorylation of FAK at tyrosines 861
and 925 by SFKs leading to focal adhesion plasticity [21]. FAK
phosphorylation at Tyr861 was unaffected by c-Yes knock-down,
in contrast to c-Src knock-down (Fig. S2B). Accordingly, FAK
silencing failed to induce similar cell clusters (Fig. S3A),
suggesting that the morphological effect induced by c-Yes
depletion is not due to a defect on cell spreading. Since
localisation of b-catenin at the membrane has been reported to
be in part regulated by SFKs [17,20], we examined its
localisation. In HT29 cells, b-catenin is present in majority at
cell-cell junctions and the cytoplasm. Using confocal microscopy
we observed that c-Yes knock-down induced a strong accumu-
lation of b-catenin and E-Cadherin at the cell-cell junctions
(Fig. 2A and S4). Biochemical analysis of b-catenin cytosolic and
membrane fractions tightly correlated with these observations
(Fig. 2B). In contrast, c-Src knock-down had only a mild effect on
b-catenin membrane accumulation (Fig. 2A and B). This suggests
that cell clustering induced by c-Yes depletion primarily relies on
a modulation of adherent junctions.
c-Yes knock-down affects b-catenin signalling in colon
cancer cells
We next examined whether b-catenin accumulation at cell-cell
junction has functional consequences on its ability to drive
transcription of its cognate genes. Amongst its target genes,
VEGF-A and EphB3 have demonstrated to be highly sensitive to a
reduction of b-catenin activity [22]. As shown in figure 2C, a 60%
reduction in VEGF-A and EphB3 mRNA levels was observed
upon c-Yes depletion. Accordingly, confocal microscopy analysis
revealed some nuclear b-catenin exclusion upon c-Yes depletion
(Fig. S4). However no such a change in nuclear b-catenin level
could be obtained by biochemical analysis, probably because of its
low abundance in nuclear compartments of HT29 cells and the
low sensitivity of the biochemical approach as compared to
confocal microscopy analysis (not shown). Interestingly, no
significant reduction in VEGF-A or EphB3 mRNA was observed
in c-Src depleted cells, showing specificity among Src members
(Fig. 2C).
c-Yes silencing leads to increased apoptosis and reduced
tumour growth
We next analysed the consequences of c-Yes knock-down on cell
growth and survival. We first observed that c-Yes specific
depletion consistently showed a doubling time 1.4 fold longer
than control HT29 cells (Fig. S5B). We measured the distribution
of cells at each phase of the cell cycle by flow cytometry and
observed only 1.6-fold increase in the fraction of cells in G2/M
when compared to cells expressing a scramble version of c-Yes
shRNA (srb1), consistent with an important role of SFK in cell
division [10] (Fig. S5A). Our cytometry experiments also showed a
4 to 6 fold increase in sub-G1 cells in c-Yes depleted cells (Fig.
S5A). Consistent with these observations, these cells showed an
increase in apoptosis as revealed by annexin V labelling (Fig. 3A)
and caspase activity (.1000 fold as compared to control cells) (Fig.
c-Yes Oncogenic Signalling in Colon Cancer Cells
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survival by studying the potential of cells for substrate-independent
growth. We found that c-Yes silencing induced 85% decrease in
the number of colonies grown in soft agar (Fig. 3B). Moreover,
colonies were smaller in size when compared to the ones obtained
with control cells (not shown). Again, c-Src depletion induced a
milder effect. We next wished to confirm this data in vivo,b y
implanting these cells sub-cutaneously into SCID mice. In contrast
to control or c-Src knock-down cells, c-Yes-deficient cells failed to
produce large tumors (Fig. 3C). Western blotting of tissue extracts
confirmed that the small masses generated by these cells had
reduced c-Yes levels (Fig. S6). We concluded to an important
function for c-Yes in growth/survival of HT29 cells.
c-Yes silencing reduces cancer cell migration and liver
metastasis in nude mice
We next evaluated the impact of c-Yes knock-down on cell
invasion. c-Yes knock-down reduced cell migration by 75% in a
Boyden chamber assay in vitro, whereas c-Src knock-down gave a
milder effect (Fig. 3D). Accordingly, c-Yes silencing also affected
the capacity of cells to invade liver tissue in an experimental
metastasis assay. Strikingly, none of the mice injected with c-Yes
Figure 1. Stable c-Yes but not c-Src knock-down results in cell clusters. (A) Western blots showing c-Yes and c-Src proteins in a lysate (WCL)
of CRC cell-lines. (B) c-Yes and c-Src proteins in lysates of HT29 cells expressing shRNA constructs. Srb1 shRNA is a control shRNA and srb2 a control
version of c-Src lentiviral shRNA. (C) DIC microscopy images showing the morphology of HT29 cells expressing shRNAs. (D) Confocal microscopy
reconstitution HT29 cells expressing shRNA and stained with b-catenin antibodies.
doi:10.1371/journal.pone.0017237.g001
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cells that led to the macroscopically visible metastasis (.2 mm) in
the livers of all mice tested (Table 1). Again, c-Src knock-down
resulted in a moderate reduction in the extent of liver metastases
(Table 1). These results indicate that c-Yes play important roles in
the metastatic capacity of colon carcinoma cells.
Figure 2. b-catenin accumulates at cell junctions and reduces expression of b-catenin target genes in c-Yes knock-down cells.
(A) Confocal microscopy images of b-catenin in HT29 cells expressing indicated shRNAs. (B) Western blot analysis showing the level of b-catenin in
membrane (mb) and cytosolic (cyto) fractions from cells expressing indicated shRNAs. The level of Transferrin Receptor (TR) is also shown and was
used as a control of membrane fractions. (C) VEGF-A and EphB3 quantitative RT-PCR in cells expressing indicated shRNA. RNA is expressed relative to
expression in srb1 or srb2 control shRNA expressing cells.
doi:10.1371/journal.pone.0017237.g002
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Finally, we analysed the capacity of c-Src to reverse the
phenotypes of c-Yes depleted cells. c-Src or an shRNA-resistant
version of c-Yes (R-Yes) was transduced into c-Yes depleted cells
by retroviral infection. c-Yes levels were restored by 50% and c-
Src levels were increased by .3-fold above endogenous c-Src
levels (Fig. 4A). Ectopic c-Src was very active in these cells as
shown by the increase in global tyrosine phosphorylation. In
contrast, partial restoration of c-Yes levels only poorly affected
global tyrosine phosphorylation (Fig. 4A). Nevertheless, stable
introduction of the R-Yes construct was sufficient to reverse the
clustering phenotype of c-Yes knock-down cells, (Fig. 4B). This
effect was dependent upon the catalytic activity of c-Yes as it was
not observed by the expression of the kinase-defective R-Yes-K
2
construct. In agreement with this notion, we also observed that the
increase of b-catenin membrane localisation due to c-Yes silencing
can be restored by R-Yes. Immunofluorescence experiments
confirmed the restoration of intracellular b-catenin by expression
Figure 3. c-Yes knock-down increases apoptosis and decreases growth in soft-agar and in mouse xenografts. (A). Percentage of
apoptotic cells obtained after stable transduction of indicated shRNA and revealed by Annexin V (black box) and propidium idodide (white box).
(B) c-Yes depletion inhibits cell growth in soft-agar. Number of colonies obtained from HT29 cells expressing indicated shRNA grown in soft-agar
conditions. The mean 6 SD (n.3) is shown. (C) c-Yes depletion inhibits subcutaneous tumour growth in nude mice. Cells expressing indicated shRNA
were implanted subcutaneously in five SCID mice. (D) c-Yes depletion inhibits cell migration. Statistical analysis of the number of HT29 cells
expressing indicated shRNA/field that have migrated in Boyden chamber assays in the presence of EGF (20 ng/ml). The mean 6 SD (n.3) is shown.
doi:10.1371/journal.pone.0017237.g003
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2 was unable to show
this effect confirming c-Yes kinase-dependent signalling towards b-
catenin and cell-cell adhesion (supplementary Fig. S7). Interest-
ingly, we found that in our conditions, ectopic c-Src also reversed
the clustering phenotype of c-Yes knock-down cells to some extent
and restored cytosolic b-catenin (Fig. 4B and C). This effect may
be explained by the relative high level of expressed c-Src to
endogenous c-Yes (10-15 fold), so that signalling specificity is lost.
Moreover, this data indicates that c-Yes signalling specificity can
be overcome by the expression of a large excess of c-Src. Finally,
we wished to address whether c-Src shares c-Yes oncogenic
activities in these CRC cells. Interestingly, c-Src overexpression
neither restored anchorage-independent growth nor cell migration
of c-Yes depleted cells, unlike R-Yes (Fig. 5A and B). Again, the
effect of c-Yes on cell growth was kinase-dependent as it was not
observed with R-Yes-K
2 (Fig. 5A). Surprisingly, a different
situation was observed on cell migration. While the R-Yes
construct selectively restored cell migration of c-Yes-depleted
HT29 cells, R-Yes-K
2 also restored this biological property
(Fig. 5B). This suggests that c-Yes migratory signalling is not
dependent upon its kinase activity, unlike cell growth.
Discussion
In this paper we show that in HT29 cells, down-regulation of c-
Yes levels is sufficient to induce epithelial characteristics such as
elevated localisation of b-catenin at cell-cell-adhesions. c-Yes
knock-down also leads to an increase in apoptosis, reduced
substrate-independent growth, loss of the capacity to form sub-
cutaneous tumors in nude mice and to invade tissue in an
experimental metastasis model. Similar results have been obtained
in additional CRC cells tested, indicating that this oncogenic
function of c-Yes is not specific to the cell-line used in this study (F.
Dubois and S. Roche, unpublished data). Our data uncover for the
first time a unique function for c-Yes in b-catenin signalling and
tumorigenicity of CRC cells. Moreover, our results show a milder
inhibitory effect following c-Src silencing, suggesting that c-Yes
could be a more important player than c-Src in CRC
tumorigenesis. Nevertheless, it remains possible that the low effect
of c-Src knock-down described here is due to residual deregulated
c-Src activity in HT29 cells being sufficient to maintain a
transformed phenotype. Based on the relative expression of c-
Src and c-Yes in parental cells and the level of knock-down
achieved, we deduced that the residual c-Src mRNA copy number
achieved with our shRNA strategy is comparable to the parental
cell c-Yes mRNA copy number (Figure S1A). Therefore, a shRNA
approach targeting c-Src levels more efficiently may address this
issue unambiguously. Nevertheless, c-Src silencing obtained with
our strategy was sufficient to reduce invasion in vivo approximately
by half, while having no effect on subcutaneous tumour growth.
This suggests that CRC metastatic invasion is more sensitive to c-
Src knock-down than primary tumour growth, thus predicting a
selective therapeutic effect of SFK inhibitors on metastasis.
Our data show that c-Yes transforming activity is not redundant
to that of c-Src, although the latter is predominantly expressed in
these tumours. The exact selective mechanism downstream of c-
Yes is an important issue that needs to be addressed. In this
regard, we believe that one important mechanism may rely on
specific subcellular localisation of SFK family members, leading to
phosphorylation of specific substrates. This hypothesis is sustained
by the specific localisation of c-Yes in cholesterol-enriched
microdomains found at adherent and tight junctions, probably
due to an additional palmitoylation site present in c-Yes.
Accordingly, several labs including ours have shown that this
membrane partitioning regulates SFK signalling specificity leading
to mitogenesis [23] and neoplastic transformation [12,24]. An
additional mechanism for selective signalling may involve
substrates that interact with the unique, SH3 or SH2 domains of
these SFK. The nature of these c-Yes partners in CRC is currently
unknown, but some obvious candidates include components of the
adherens junctions such as E-cadherin and b-catenin. Accordingly,
our report suggests that one mechanism by which c-Yes regulates
its oncogenic activity is by modulation of b-catenin subcellular
localisation at the adherens junctions counteracting its nuclear
transcriptional activity, this cellular process being regulated by
tyrosine phosphorylation. Interestingly, the fact that c-Src can
restore cytosolic b-catenin while having no effect on cell
transforming activities of c-Yes depleted cells suggests that c-Yes
may induce additional signalling pathways to ensure neoplastic
properties of CRC cells. A phospho-proteomic analysis uncovering
c-Yes selective substrates is under current investigation to address
this issue.
Finally, our data also reveal an unanticipated role of c-Yes in
migration independent of its catalytic activity. An adapter function
of SFK has been already documented with the example of c-Src
during integrin signalling leading to cell spreading [1]. Therefore,
we anticipate a similar adaptor function for c-Yes, implicating
specific c-Yes SH2/SH3 binders to be identified. This observation
may have important implication in cancer therapy involving SFK
catalytic inhibitors and may explain, at least in part, the
discrepancy observed between the dramatic loss of tumorigenicity
in c-Yes-depleted cells compared to mild effects of SFK kinase
inhibitors in vivo. Alternatively, pan-SFK pharmacological
inhibitors could affect the activity of other kinase or non-kinase
targets that may counter-act the effect of selectively inhibiting c-
Yes inhibition. Given the difficulty in obtaining specific c-Yes
inhibitors, therapeutic siRNAs would be necessary to test this
hypothesis. In conclusion, these data would predict therapeutic
value of siRNA targeting c-Yes in CRC and confirm SFKs as
attractive therapeutic targets in this cancer.
Materials and Methods
2.1 Reagents
[c
32P]ATP was purchased from Amersham. Epithelial Growth
Factor, Hexadimethrine Bromide, G418 and Puromycin from
Sigma Aldrich (St Quentin, France). SFK antibodies (cst1) were
described in [25]. Sam68 was purchased from Santa Cruz. Src
specific (2.17) antibody was a generous gift of Dr S. Parsons
(University of Virginia, VA, USA). c-Yes and b-catenin antibodies
Table 1. c-Yes knock-down inhibits liver metastasis after
intrasplenic injection.
Metastatic index
HT29 cells
Micro-metastases
(,2 mm) Metastases (.2 mm)
parental 0.87 3
srbl 1 2.5
c-Yes 0.12 0
c-Src 0.66 2
Cell expressing indicated shRNA were injected in the spleen of SCID mice and
livers analysed 30 days after surgery. Metastases (.2 mm) and micrometastases
(,2 mm) were scored according to the relative extent of invaded tissue and a
metastatic index calculated as described in Material and Methods is shown.
doi:10.1371/journal.pone.0017237.t001
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antibodies were from Upstate. Lyn, E-cadherin (H-108) antibodies
were from Santa Cruz. Phospho-Src (Y418) and phospho-FAK
(Y861) were from Biosource. Transferrin Receptor (TR) antibody
was from Zymed. a-pTyr 4G10 and anti-atubulin were a gift from
P. Mangeat and N. Morin respectively (CRBM, Montpellier).
Alexa Fluor 488 dye conjugated goat a-mouse or goat a-rabbit
and Alexa Fluor 594 dye conjugated goat anti-Mouse or goat anti-
rabbit were from Alexa. siRNA SmartPools (c-Src, c-Yes, Lyn,
FAK) were from Dharmacon. c-Yes shRNA sequence was: sense:
39-cagaaucccuccaugaauuuu; antisense: 59-aauucauggagggauucu-
guu. A double stranded version containing the loop sequence
Figure 4. High expression of c-Src can rescue cell adhesive properties and cytosolic b-catenin of c-Yes depleted cells. (A). Western
blotting showing the level of c-Src, c-Yes, phosphotyrosine content (4G10) and tubulin as a control of HT29 cells expressing indicated shRNA that
were infected with control virus (mock) or viruses expressing indicated SFK construct. (B) Restoration of cell morphology by c-Yes or c-Src re-
introduction. Cell morphology of c-Yes depleted HT29 cells that were infected with control virus (mock) or viruses expressing indicated SFK construct.
(C) Restoration of b-catenin localisation by c-Yes and c-Src expression. Western blot analysis showing the level of b-catenin in membrane (mb) and
cytosolic (cyto) fractions from cells expressing indicated shRNA and infected with indicated virus. The level of Transferrin Receptor (TR) is also shown
and was used as a control of membrane fractions.
doi:10.1371/journal.pone.0017237.g004
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pSilencer2.1-U6 neo (Ambion). A pSilencer control shRNA
(Ambion) was used. An shRNA-resistant version of c-Yes cDNA
(called R-Yes) was generated by site-directed mutagenesis
(QuickChange II XL-Stratagen) of full-length human c-Yes cDNA
and inserted into pcDNA.1DV5HisTopo (Invitrogen). Primers
used were: 59-ccctcagggctgtccagagtcgctgcacgaattgatgaatc-39 and
59-gattcatcaattcgtgcagcgactctggacagccctgaggg-39. To generate a
‘‘kinase-dead’’ version of R-Yes (R-Yes-K
2), Lysine 308 was
mutated to Methionine. Primers used were: 59-gcaatcaaaacac-
taatgccaggtacaatgatgccagaagc-39 and reverse: 59-gcttctggcatcattg-
tacctggcattagtgttttgattgc-39. Human cDNA for Src, R-Yes and R-
Yes-K
2 were subcloned into pBABE puro-retroviral vector.
2.2. Cell culture, transfections and infections
HT29, SW620, SW480, HCT116 and Colo205 cell lines were
obtained from ATCC and grown at 37uC and 5% CO2 in
RPMI containing 10% fetal calf serum (Sigma). Transfections of
siRNAs into HT29 cells were carried out using 3 ml Lipofecta-
mine 2000 reagent plus 3 ml of SmartPool solution at 20 mM.
To generate stable shRNA c-Yes clones, pSilencer-Yes shRNA
or sh-control Ambion construct (srb1) were transfected into
HT29 cells and neomycin-resistant colonies were amplified
(400 mg/ml). To generate stable shRNA Src pools, HT29 cells
were transduced with Sigma MISSION
TM shRNA vectors for
Src (SHVRSC-TRCN0000038149; MOI 100 or 300) or a non-
target scramble control sequence (srb2) (SHC002V; MOI 100).
For restoration experiments, shRNA Yes pool was transduced
with c- Src, R-Yes or R-Yes-K
2 constructs by retroviral
infection as in [26].
2.3 Cell growth and migration
For anchorage-independent cell growth, 0.67% agar in medium
was layered on the bottom of a 12 wells plate and 2 000 cells/well
were seeded on the top of this layer in 0.33% agar-medium. After
18–21 days colonies having .50 cells were scored positive. Cell
migration assays were performed in Boyden chambers (BD
Bioscience) using 50,000 cells for 2 h.
2.4. Biochemistry
Cell lysate, immunoprecipitation, Western-blotting and in vitro
kinase assays for SFKs were preformed as described in [27].
Membrane/cytoplasm fractionations were done using Subcellular
Protein Fractionation Kit according to the manufacturer’s
instructions (Pierce, ThermoScientific). AnnexinV/PI labelling
and caspase assays were performed as follows: Cells were washed
with PBS without calcium/magnesium and once with annexin V
buffer (10 mM Hepes, 2.5 mM CaCl2, 140 mM NaCl. 20 ml
annexin V-Alexa fluor 488 conjugate (Invitrogen) and 10 ml
propidium iodide (PI) at 2.5 mg/ml were added and incubated
15 min in the dark. Readings were performed with an XL/MCL
flow cytometer (Beckman Coulter). Alexa fluor 488 and PI
fluorescences were collected (520 nm and 630 nm filters).
2.5. RNA extractions and RT-QPCR
HT29 were scrapped in 1 ml TRIZOLH (Invitrogen P/N
15596-026) and total RNA was extracted according to manufac-
turer’s protocol. Quality of RNA was estimated with the ratio
28S/18S RNA in the sample using Agilent Bioanalyser 2100.
Reverse transcription was performed with the High capacity
cDNA reverse transcription kit (Applied Biosystems P/N
4374966). PCR was performed using an Applied Biosystem 7300
Real time PCR system and TaqMan Assay (Applied Biosystem):
Yes (Hs00736972_m1), Src (Hs00178494_m1), VEGF-A (Hs009
00055_m1), EPHB3 (Hs00177903_m1), 18s (Hs99999901_s1) and
GAPDH (Hs99999905_m1). RNA 18S and GAPDH endogenous
controls were used for quantification.
Figure 5. c-Src expression does not restore transforming
properties of c-Yes depleted cells. (A) c-Src expression does not
restore cell growth in soft-agar of c-Yes depleted cells. Number of
colonies obtained from HT29 cells expressing indicated shRNA and
infected with shown retroviruses. The mean 6 SD (n.3) is shown. (B) c-
Src expression does not restore cell migration of c-Yes depleted cells.
(B) Statistical analysis of the number of indicated HT29 cells/field that
have migrated in Boyden chamber assays in the presence of EGF
(20 ng/ml). The mean 6 SD (n.3) is shown. * P,0.05 and ** P,0.01
using a student’s t-test.
doi:10.1371/journal.pone.0017237.g005
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Murine subcutaneous tumor growth were performed as follows:
1610
7 cells viable cells were inoculated subcutaneously (into the
flank) to 6–8 week old female SCID mice (Charles River). Tumors
size measured with calipers. At days 21 or 30, mice were sacrificed,
subcutaneous tumors were removed and processed for analysis.
Murine liver invasion assays were performed as follows: female
SCID mice were purchased from Charles River and maintained in
a specific pathogen-free environment. 1.5610
6 were inoculated
into the spleen of anaesthetized SCID mice. The spleen was
removed after 3 minutes following the end of cell injection. Mice
were monitored daily for up to 30 days. At day 30, mice were
sacrificed, livers were removed and processed for histo-patholog-
ical analysis by a trained pathologist. Micrometastases (,2 mm) or
metastases (.2 mm) were quantified by the relative surface
covered by invading cells. Micrometastases were scored as
minimal (one single point), +, ++ or +++. Metastases were scored
as +, ++ or +++. To obtain a weighed average of the level of
invasion observed in each group of three to four mice, a numerical
score was attributed to each relative value: minimal=0.5, +=1.0,
++=2.0 and +++=3.0. These scores were multiplied by the
number of mice in one group presenting the score and the total of
added values divided by the number of mice in one group. The
‘‘metastatic index’’ is calculated for each group as:
Metastatic index~
Sns x score
ng
where ns is the number of mice in one group presenting a
particular score in the scale and ng is the total number of mice in
one group. All experiments on live animals were performed in
accordance with institutional and national guidelines and
regulations. Protocols have been approved by the Institut de
Recherches Servier Ethics Committee (ID for both protocols:
EFFIXENOSOU; Approval for both protocols on 26 January
2009).
Supporting Information
Figure S1 SFK expression in cells expressing indicated
shRNA.
(TIF)
Figure S2 Transient c-Yes but not c-Src knock-down
results in cell clusters. A. c-Src and c-Yes level and activity
in cells transfected with indicated siRNA. B. c-Src, but not c-Yes
knock-down inhibits FAK phosphorylation at Tyr861. C. Tran-
sient c-Yes knock-down induces cell-cell clustering.
(TIF)
Figure S3 Fak and Lyn knock-down does not induce cell
clusters.
(TIF)
Figure S4 Confocal microscopy analysis of E-cadherin
and b-catenin localisation in c-Yes knock-down cells.
(TIF)
Figure S5 Yes knock-down modify cell cycle and
increase apoptosis. A. c-Yes knock-down increase SubG1
and G2M cell cycle fractions. B. c-Yes knock-down increase cell
doubling time (measure in hours by BrDu incorporation). C. c-Yes
knock-down increase caspase activity (in fluorescence units).
(TIF)
Figure S6 c-Src and c-Yes levels in samples 17 or 31
days after implantation in mice of HT29 cells expressing
indicated shRNA.
(TIF)
Figure S7 R-Yes, but not R-Yes-K
- construct restores
b-catenin localisation in HT29 c-Yes knock-down cells.
(TIF)
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